Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 2 (2005), Issue 8 (August)

1. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
   Am J Hematol, 79(4): 288-90. [Abstract] [Full-text]
2. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
   Am J Hematol, 79(4): 257-61. [Abstract] [Full-text]
3. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
   Am J Hematol, 79(4): 267-73. [Abstract] [Full-text]
4. Erythrophagocytosis by dysplastic neutrophils in chronic myelomonocytic leukemia and subsequent transformation to acute myeloid leukemia.
   Am J Hematol, 79(4): 340-2. [Abstract] [Full-text]
5. Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma.
   Am J Hematol, 79(4): 294-8. [Abstract] [Full-text]
6. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
   Am J Hematol, 79(4): 329-31. [Abstract] [Full-text]
7. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
   Bone Marrow Transplant, 36(2): 157-62. [Abstract] [Full-text]
8. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
   Leukemia, 19(7): 1161-8. [Abstract] [Full-text]
9. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
   Leukemia, 19(7): 1224-8. [Abstract] [Full-text]
10. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Leukemia, 19(7): 1153-60. [Abstract] [Full-text]
11. Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
    Pediatr Blood Cancer. [Abstract] [Full-text]
12. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Ann Hematol, 84(9): 557-64. [Abstract] [Full-text]
13. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Blood, 106(4): 1183-8. [Abstract] [Full-text]
14. Global approach to the diagnosis of leukemia using gene expression profiling.
    Blood, 106(4): 1189-98. [Abstract] [Full-text]
15. Drug therapy for acute myeloid leukemia.
    Blood, 106(4): 1154-63. [Abstract] [Full-text]
16. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.
    Blood, 106(4): 1419-22. [Abstract] [Full-text]
17. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).
    Blood, 106(4): 1369-75. [Abstract] [Full-text]
18. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.
    Blood, 106(4): 1362-8. [Abstract] [Full-text]
19. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
    Blood. [Abstract] [Full-text]
20. Acute myelogenous leukemia with tetrasomy 8 is a disease with a poor prognosis.
    Cancer Genet Cytogenet, 161(1): 78-81. [Abstract] [Full-text]
21. Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement.
    Leuk Lymphoma, 46(8): 1223-7. [Abstract] [Full-text]
22. CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives.
    Leuk Lymphoma, 46(8): 1115-20. [Abstract] [Full-text]
23. KDR and Sema3 genes expression in bone marrow stromal cells and hematopoietic cells from leukemia patients and normal individuals.
    Hematology, 10(4): 307-12. [Abstract] [Full-text]
24. Monitoring structural changes in cells with high-frequency ultrasound signal statistics.
    Ultrasound Med Biol, 31(8): 1041-9. [Abstract] [Full-text]
25. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Semin Oncol, 32(4): S3-10. [Abstract] [Full-text]
26. Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study.
    Hum Pathol, 36(7): 797-805. [Abstract] [Full-text]
27. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Cancer, 104(4): 788-93. [Abstract] [Full-text]
28. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Cancer Immunol Immunother, 54(10): 953-70. [Abstract] [Full-text]
29. Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.
    Oncogene. [Abstract] [Full-text]
30. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Scand J Immunol, 62(1): 86-98. [Abstract] [Full-text]
31. Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
    Cancer Immunol Immunother, 54(10): 933-43. [Abstract] [Full-text]
32. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
    Ann Hematol. [Abstract] [Full-text]
33. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
    J Thromb Haemost. [Abstract] [Full-text]
34. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
    Leuk Res. [Abstract] [Full-text]
35. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.
    Acta Haematol, 114(2): 78-83. [Abstract] [Full-text]
36. Expression of leptin receptors in mononuclear cells from myelodysplastic syndromes and acute myeloid leukemias.
    Acta Haematol, 114(2): 71-7. [Abstract] [Full-text]
37. The FLT3 Internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Cancer Res, 65(16): 7338-47. [Abstract] [Full-text]
38. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Cancer Res, 65(16): 7086-90. [Abstract] [Full-text]
39. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
    J Thromb Haemost, 3(9): 1985-92. [Abstract] [Full-text]
40. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.
    Nucleic Acids Res, 33(14): e128. [Abstract] [Full-text]
41. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 chinese patients.
    Int J Hematol, 82(1): 48-54. [Abstract] [Full-text]
42. BMI-1 Is Highly Expressed in M0-Subtype Acute Myeloid Leukemia.
    Int J Hematol, 82(1): 42-7. [Abstract] [Full-text]
43. Identification of a Chromosomal Breakpoint and Detection of a Novel Form of an MLL-AF17 Fusion Transcript in Acute Monocytic Leukemia with t(11;17)(q23;q21).
    Int J Hematol, 82(1): 38-41. [Abstract] [Full-text]
44. Runx1/AML1 in Normal and Abnormal Hematopoiesis.
    Int J Hematol, 82(1): 1-8. [Abstract] [Full-text]
45. Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL.
    Eur J Haematol, 75(3): 185-92. [Abstract] [Full-text]
46. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.
    Leukemia. [Abstract] [Full-text]
47. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes.
    Leukemia. [Abstract] [Full-text]
48. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    J Clin Oncol, 23(24): 5705-17. [Abstract] [Full-text]
49. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    J Clin Oncol, 23(24): 5675-87. [Abstract] [Full-text]
50. Mutations in nucleophosmin NPM1 in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
    Blood. [Abstract] [Full-text]
51. Are MTT assays the right tool to analyze drug resistance caused by ABC-transporters in patient samples?
    Leuk Lymphoma, 46(9): 1357-63. [Abstract] [Full-text]
52. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
    J Clin Oncol, 23(24): 5728-38. [Abstract] [Full-text]
53. ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.
    Prostate. [Abstract] [Full-text]
54. Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias.
    Thromb Haemost, 94(2): 454-9. [Abstract] [Full-text]
55. MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia.
    Leuk Res, 29(10): 1223-6. [Abstract] [Full-text]
56. Telomerase activity in myelodysplastic syndromes.
    Leuk Res, 29(10): 1131-9. [Abstract] [Full-text]
57. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
    Expert Rev Anticancer Ther, 5(4): 585-90. [Abstract] [Full-text]
58. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
    Leuk Res, 29(10): 1109-16. [Abstract] [Full-text]
59. Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers.
    Leuk Res, 29(10): 1191-9. [Abstract] [Full-text]
60. S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents.
    Leuk Res, 29(10): 1181-90. [Abstract] [Full-text]
61. Effect of transcription-factor concentrations on leukemic stem cells.
    Blood, 106(5): 1519-24. [Abstract] [Full-text]
62. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
    Blood, 106(5): 1817-23. [Abstract] [Full-text]
63. The G-CSF receptor carboxyl terminus, truncated in AML/SCN, is required for induction of a Stat5 protease activity.
    Leuk Res, 29(10): 1153-62. [Abstract] [Full-text]
64. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia.
    Clin Cancer Res, 11(16): 5708-17. [Abstract] [Full-text]
65. Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders.
    Mod Pathol. [Abstract] [Full-text]
66. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia.
    Mod Pathol. [Abstract] [Full-text]
67. First report of donor cell derived acute leukemia as a complication of umbilical cord blood transplantation.
    Blood. [Abstract] [Full-text]
68. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
    Leukemia, 19(9): 1567-72. [Abstract] [Full-text]
69. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Leukemia, 19(9): 1536-42. [Abstract] [Full-text]
70. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
    Leukemia, 19(9): 1543-9. [Abstract] [Full-text]
71. Leukomogenic factors downregulate heparanase expression in acute myeloid leukemia cells.
    Biochem Biophys Res Commun, 335(4): 1115-22. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.